Otsuka Pharmaceutical Co. Ltd. said a federal court ruled Monday that patents protecting the active ingredient behind the schizophrenia drug Abilify are valid and enforceable.
The Japanese drugmaker said Tuesday the ruling by the U.S. District Court for the District of New Jersey maintains patent and regulatory protection for the drug in the United States at least until April 20, 2015. Otsuka had filed litigation against several companies that were seeking approval to make generic versions of the drug.
Otsuka discovered Abilify, which is approved for schizophrenia, bipolar disorder and depression. It shares marketing with U.S. drugmaker Bristol-Myers Squibb Co.
Shares of Bristol-Myers fell 24 cents to $26.08 in Tuesday morning trading.